Successful Phase 3 results for Hatchtech Xeglyze trials

Hatchtech Pty Ltd this week announced successful results for its phase 3 trials of Xeglyze™ Lotion, a novel lice and egg treatment.

The studies comprised 704 subjects receiving a single ten-minute application of Xeglyze™ Lotion, resulting in 81.5% of subjects remaining lice free through to the 14-day follow-up point. This represents a statistically significant increase in anti-lice treatment versus the control.

There were few adverse effects reported, and none were serious in nature.

The active ingredient of Xeglyze™ Lotion is known to inhibit key pathways in the life cycle of the head louse, including the egg, supported by both published results and patent information.

Hatchtech intend to file a New Drug Application with the US Food and Drug Administration in 2015.